AC Immune
raises
USD
43.5
million
(CHF
42.7
million)
in Financing Round
E
AC Immune SA today announced that it raised approximately USD 43.5 million (CHF 42.7 million ) in a private financing in which it issued Series E preferred shares to certain institutions and existing shareholders . The p roceeds of the financing , together with exist ing cash resources, will be used by AC Immune to advance its clinical and pre - clinical therapeutic and diagnostic product pipeline in Alzheimer’s disease and other neurodegenerative diseases . About AC Immune
AC Immune is a clinical stage Swiss - based biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platfo rms create antibodies, small molecules and vaccines to address a broad spectrum of neurodegenerative indications. Alzheimer’s disease (AD) is the largest indication addressed by AC Immune’s products but the company’s therapies are designed to address other neurodegenerative diseases such as Parkinson’s, Down syndrome, and g laucoma as well . The Company ’s pipeline featur es seven therapeutic and three diagnostic product candidates . For further information please contact:
AC Immune
Prof. Andrea Pfeifer
Chief Executive Officer
Phone: +41 - 21 - 693 91 21
E - mail: andrea.pfeifer@acimmune.com
Eva Schier
Corporate Communications Manager
Phone: +41 - 21 - 693 91 34
E - mail: eva.schier@acimmune.com
Nick Miles
Senior Consultant
Cabinet Privé de Conseils s.a.
Mobile : +41 79 678 76 26
E - mail : miles@cpc - pr.com
In the US
Ted Agne
The Communications Strategy Group Inc.
Phone: +1 781 631 3117
E - mail: edagne@comstratgroup.comed
AC Immune SA today announced that it raised approximately USD 43.5 million (CHF 42.7 million ) in a private financing in which it issued Series E preferred shares to certain institutions and existing shareholders . The p roceeds of the financing , together with exist ing cash resources, will be used by AC Immune to advance its clinical and pre - clinical therapeutic and diagnostic product pipeline in Alzheimer’s disease and other neurodegenerative diseases . About AC Immune
AC Immune is a clinical stage Swiss - based biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platfo rms create antibodies, small molecules and vaccines to address a broad spectrum of neurodegenerative indications. Alzheimer’s disease (AD) is the largest indication addressed by AC Immune’s products but the company’s therapies are designed to address other neurodegenerative diseases such as Parkinson’s, Down syndrome, and g laucoma as well . The Company ’s pipeline featur es seven therapeutic and three diagnostic product candidates . For further information please contact:
AC Immune
Prof. Andrea Pfeifer
Chief Executive Officer
Phone: +41 - 21 - 693 91 21
E - mail: andrea.pfeifer@acimmune.com
Eva Schier
Corporate Communications Manager
Phone: +41 - 21 - 693 91 34
E - mail: eva.schier@acimmune.com
Nick Miles
Senior Consultant
Cabinet Privé de Conseils s.a.
Mobile : +41 79 678 76 26
E - mail : miles@cpc - pr.com
In the US
Ted Agne
The Communications Strategy Group Inc.
Phone: +1 781 631 3117
E - mail: edagne@comstratgroup.comed
